Search

Displaying results 2071 - 2080 of 10000 in total
  1. Drug

    Trioxsalen

    go.drugbank.com/drugs/DB04571
    ApprovedWithdrawn

    The photoactivated form produces interstrand linkages in DNA resulting in cell apoptosis. … Like other psoralens it causes photosensitization of the skin.

  2. Drug

    Alemtuzumab

    go.drugbank.com/drugs/DB00087
    ApprovedInvestigational

    Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin.[L43397] Alemtuzumab was approved by the FDA in 2001. … The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G).

  3. Drug

    Gallium nitrate

    go.drugbank.com/drugs/DB05260
    ApprovedInvestigational

    [L47726] Apart from cancer-related hypercalcemia, gallium nitrate has been studied in arthritis, autoimmune disorders, and tumours.[A260830] … [A17097] GANITE, a product of gallium nitrate previously used to treat cancer-related hypercalcemia, was discontinued from marketing in the US for reasons other than safety or effectiveness.

  4. Drug

    Fospropofol

    go.drugbank.com/drugs/DB06716
    ApprovedIllicitInvestigationalWithdrawn

    FDA approved in December 2008. Fospropofol is a Schedule IV controlled substance in the United States under the Controlled Substances Act. … Fospropofol is a water soluble prodrug and is converted to propofol in the liver. Fospropofol is a short acting hypnotic/sedative/anesthetic agent.

  5. Drug

    Hydroxyurea

    go.drugbank.com/drugs/DB01005
    ApprovedInvestigational

    [A262596] It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. … [A262601] Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, hydroxyurea is used sparingly in clinical settings, largely due to lack of knowledge and adherence, the

    Synonyms: N-Hydroxyurea, N-Carbamoylhydroxylamine
  6. Drug

    Eflapegrastim

    go.drugbank.com/drugs/DB15001
    ApprovedInvestigational

    in which the patient develops an infection during a period of significant neutropenia. … [L43135] In September 2022, eflapegrastim was approved by the US FDA as a prophylactic against infection, as manifested by febrile neutropenia, in patients receiving certain myelosuppressive anti-cancer

  7. Drug

    Momelotinib

    go.drugbank.com/drugs/DB11763
    ApprovedInvestigational

    Momelotinib works to block the JAK-signal transducer and activator of transcription (STAT) signalling pathway, which is aberrant in MF.[A261561, A261566, A261571] … MF includes primary MF (PMF), post-polycythemia vera (PV) MF, and post-essential thrombocythemia (ET) MF. Clinical manifestations of MF include anemia and thrombocytosis.

    Synonyms: N-(CYANOMETHYL)-4-(2-(4-MORPHOLINOANILINO)PYRIMIDIN-4-YL)BENZAMIDE
  8. Drug

    Tagraxofusp

    go.drugbank.com/drugs/DB14731
    ApprovedInvestigational

    a myeloid malignancy in the dendritic cell lineage. … It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in _Escherichia coli_.

  9. Drug

    Encorafenib

    go.drugbank.com/drugs/DB11718
    ApprovedInvestigational

    Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin … Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations.

  10. Drug

    Cysteine

    go.drugbank.com/drugs/DB00151
    ApprovedInvestigationalNutraceutical

    A thiol-containing non-essential amino acid that is oxidized to form cystine.

    Mixtures: Numeta G 13 % E Emulsion zur Infusion, Numeta G 16 % E Emulsion zur Infusion